[ARNA] Arena Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 396.16 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.53 Change: 0.06 (4.08%)
Ext. hours: Change: 0 (0%)

chart ARNA

Refresh chart

Strongest Trends Summary For ARNA

ARNA is in the long-term up 179% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company?s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding243.04 M EPS0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.26% Sales Growth - Q/Q33.35% P/E65.5
P/E To EPS Growth P/S9.34 P/BV3.07 Price/Cash Per Share
Price/Free Cash Flow-3.59 ROA-16.44% ROE-46.18% ROI
Current Ratio3.61 Quick Ratio3.46 Long Term Debt/Equity0.35 Debt Ratio0.58
Gross Margin76.36% Operating Margin-243.99% Net Profit Margin-140.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities101.41 M Cash From Investing Activities-1.07 M Cash From Operating Activities-23.02 M Gross Profit8.66 M
Net Profit-24.3 M Operating Profit-21.74 M Total Assets362.29 M Total Current Assets268.62 M
Total Current Liabilities74.36 M Total Debt70.17 M Total Liabilities233.35 M Total Revenue12.26 M
Technical Data
High 52 week49.63 Low 52 week30.89 Last close43.58 Last change-0.37%
RSI72.62 Average true range2.02 Beta1.02 Volume2.08 M
Simple moving average 20 days7.91% Simple moving average 50 days9.66% Simple moving average 200 days6.16%
Performance Data
Performance Week-0.91% Performance Month6.06% Performance Quart10.83% Performance Half-2.22%
Performance Year28.63% Performance Year-to-date11.89% Volatility daily3.16% Volatility weekly7.07%
Volatility monthly14.48% Volatility yearly50.18% Relative Volume420.94% Average Volume624.51 K
New High New Low


2020-06-01 16:01:00 | Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

2020-06-01 09:30:01 | Moving Average Crossover Alert: Arena Pharmaceuticals

2020-05-28 08:30:00 | Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

2020-05-27 16:01:00 | Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

2020-05-26 08:30:00 | Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates

2020-05-22 16:30:00 | Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

2020-05-20 16:01:00 | Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-19 16:10:06 | Galecto Appoints New Chair and Strengthens Board of Directors

2020-05-13 16:01:00 | Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

2020-05-13 09:18:01 | Is Arena ARNA Stock a Solid Choice Right Now?

2020-05-10 08:18:45 | Earnings Update: Arena Pharmaceuticals, Inc. NASDAQ:ARNA Just Reported And Analysts Are Trimming Their Forecasts

2020-05-08 15:01:05 | Arena Pharmaceuticals Inc ARNA Q1 2020 Earnings Call Transcript

2020-05-08 14:56:26 | Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-08 10:39:02 | Arena Pharmaceuticals ARNA Q1 Loss Narrower Than Expected

2020-05-07 16:01:00 | Arena Announces Corporate Update and Reports First Quarter 2020 Financial Results

2020-05-06 08:30:00 | Arena Pharmaceuticals to Present at the Bank of America Securities Healthcare Conference on May 13

2020-04-30 08:30:00 | Arena Pharmaceuticals to Release First Quarter 2020 Financial Results and Provide Corporate Update on May 7

2020-04-24 09:00:00 | Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-19 08:27:45 | If You Had Bought Arena Pharmaceuticals NASDAQ:ARNA Shares Three Years Ago You'd Have Made 283%

2020-04-14 13:47:34 | ESPAÑOL • Empresas de Cannabis con Acciones el NYSE y NASDAQ: Una Lista Completa

2020-04-10 13:09:00 | Arena Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference on April 14

2020-04-07 20:05:05 | Hedge Funds Have Never Been This Bullish On Arena Pharmaceuticals, Inc. ARNA

2020-04-01 16:01:00 | Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release CR

2020-03-30 08:30:00 | Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor

2020-03-18 16:01:00 | Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-03-18 14:29:19 | Top Biotech Stocks for Q2 2020

2020-03-09 13:30:10 | 6 Cheap Health Care Stocks

2020-03-09 10:18:02 | Arena's Pipeline Holds Promise, Plunging Revenues a Concern

2020-02-28 05:38:20 | Arena Pharmaceuticals, Inc. Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

2020-02-27 13:48:51 | Edited Transcript of ARNA earnings conference call or presentation 26-Feb-20 9:30pm GMT

2020-02-27 10:40:03 | Arena Pharmaceuticals ARNA Q4 Earnings Miss, Revenues Top

2020-02-26 16:01:00 | Arena Announces Management and Program Updates and Reports Fourth Quarter and Full-Year 2019 Financial Results

2020-02-26 09:36:44 | The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

2020-02-21 16:11:00 | Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-02-20 08:30:00 | Arena Pharmaceuticals to Present at the Upcoming Investor Conferences

2020-02-19 16:06:00 | Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2019 Financial Results and Provide Corporate Update on February 26

2020-02-13 06:09:35 | Our Take On Arena Pharmaceuticals, Inc.'s NASDAQ:ARNA CEO Salary

2020-02-11 15:06:00 | Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation ECCO Congress Further Highlights Commitment to the GI Community

2020-01-17 08:16:01 | Arena's ARNA Heart Failure Candidate Gets Fast Track Status

2020-01-16 09:00:00 | FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients

2020-01-13 16:01:00 | Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary

2020-01-08 09:27:56 | 2019 Review: Top Hedge Fund Stocks vs. Arena Pharmaceuticals, Inc. ARNA

2020-01-08 08:30:00 | Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16

2020-01-07 07:57:46 | The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

2020-01-06 16:01:00 | Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years

2020-01-03 09:01:02 | Arena ARNA Expands Strategic Deal With Beacon Discovery

2020-01-02 08:30:00 | Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets

2019-12-30 08:52:47 | Is Arena Pharmaceuticals, Inc. NASDAQ:ARNA A Volatile Stock?

2019-12-19 14:32:53 | 6 Stocks With Low Price-Earnings Ratios

2019-12-13 14:31:28 | The MLB allows players to smoke marijuana